123 I-MIBG imaging for detection of anthracycline-induced cardiomyopathy.

Autor: Laursen AH; Department of Haematology, Rigshospitalet, Copenhagen, Denmark., Thune JJ; Department of Cardiology, Rigshospitalet, Copenhagen, Denmark., Hutchings M; Department of Haematology, Rigshospitalet, Copenhagen, Denmark., Hasbak P; Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark., Kjaer A; Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark., Elming MB; Department of Cardiology, Rigshospitalet, Copenhagen, Denmark., Ripa RS; Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.
Jazyk: angličtina
Zdroj: Clinical physiology and functional imaging [Clin Physiol Funct Imaging] 2018 Mar; Vol. 38 (2), pp. 176-185. Date of Electronic Publication: 2017 Mar 02.
DOI: 10.1111/cpf.12419
Abstrakt: Due to improvements in early detection and treatment of malignant disease, the population of cancer survivors is constantly expanding. Cancer survivors are faced with chemotherapy-related long-term side effects, including irreversible cardiac injury with risk of heart failure (HF). Numerous antineoplastic regimens are associated with risk of cardiac side effects, but anthracyclines in particular carry a severe risk of cardiotoxicity. Currently, serial echocardiographic evaluation of resting left ventricular ejection fraction (LVEF) is the gold standard for monitoring anthracycline-induced cardiac side effects from chemotherapy. LVEF measurements are, however, limited by their low sensitivity. A normal LVEF does not exclude cardiotoxicity and declines in LVEF are usually not observed before the occurrence of irreversible cardiomyopathy. Hence, a clinically applicable high-sensitivity diagnostic tool for early detection of chemotherapy-related cardiotoxicity is still lacking and alternative non-invasive imaging modalities are therefore being investigated. 123 I-MIBG is a noradrenaline (NA) analogue used for evaluation of cardiac adrenergic function, including assessment of HF prognosis and evaluation of HF treatment response. However, the role of 123 I-MIBG for monitoring chemotherapy-related cardiotoxicity is still unclear. Here, we review the value of 123 I-MIBG imaging for early detection and prevention of anthracycline-induced cardiomyopathy.
(© 2017 Scandinavian Society of Clinical Physiology and Nuclear Medicine. Published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: